ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-citrullinated Protein Autoantibodies (ACPAs)"

  • Abstract Number: 1679 • ACR Convergence 2024

    Differential Pharmacodynamic Changes of Circulated Immune Subsets After Treatment with Abatacept or Adalimumab in Patients with ACPA+ Early RA in the AMPLIFIED Study

    Nathanial Eddy1, Jane Buckner2, Paul Emery3, Michael Weinblatt4, Vivian Bykerk5, Andrew Cope6, Gerd Burmester7, Yoshiya Tanaka8, Gustavo Citera9, Peter Nash10, Quentin Dornic11, Peter Schafer12, Sheila Kelly13, Michael Maldonado11 and Jinqi Liu11, 1Bristol Myers Squibb, Princeton, 2Benaroya Research Institute, Seattle, WA, 3University of Leeds, Leeds, United Kingdom, 4Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, 5Hospital For Special Surgery, New York, NY, 6King's College London, London, United Kingdom, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 9Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 10Griffith University, Brisbane, Australia, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, BELLE MEAD, NJ, 13Bristol Myers Squibb, Doylestown, PA

    Background/Purpose: Despite considerable advances in pharmacologic approaches to RA management, a better understanding of the underlying immunopathology is still needed.1,2 A dysregulated immune system is…
  • Abstract Number: 0039 • ACR Convergence 2024

    Blockade of Soluble and Cell Surface PAD Activity Prevents the Generation of Citrullinated Autoantigens Recognized by RA Patients’ Serum

    Lacie Scaletta1, Teneema Kuriakose1, Sambit Nanda1, Mia Collins2, Erika Darrah3, Iain McInnes4, David Close5 and Gary Sims1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 3Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 5Early Clinical Development, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) promote inflammation and joint tissue injury and define a poor prognostic group of patients with rheumatoid arthritis (RA). Citrullinated autoantigens…
  • Abstract Number: 1871 • ACR Convergence 2024

    A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population

    Tada Vargas1, Lauren Vanderlinden2, Patrick Carry3, Kristen Demoruelle4, Marie Feser1, Katerina Kechris5, Jane Buckner6, William Robinson7, Gary Firestein8, Michael Holers1, Kevin Deane9 and Jill Norris10, 1Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2Colorado School of Public Health, Monument, CO, 3Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, 4University of Colorado Anschutz Medical Campus, Golden, CO, 5Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, 6Benaroya Research Institute, Seattle, WA, 7Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, 8University of California, San Diego, San Diego, CA, 9University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 10Colorado School of Public Health, Denver, CO

    Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
  • Abstract Number: 0045 • ACR Convergence 2024

    Proteomic Analysis of the Rheumatoid Arthritis Citrullinome Reveals an Enrichment of Citrullinated Complement Proteins

    Khushali Trivedi1, Clarissa Klenke2, Jun Kim1, Jeba Atkia Maisha2, Alina Sememenko1, XIAOBO MENG2, Mario Navarrete1, Hani El-Gabalawy2 and Liam O'Neil2, 1University of Manitoba, Winnipeg, Canada, 2University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Citrullination is a key physiological process that drives autoantibody formation in Rheumatoid Arthritis (RA). This irreversible post-translational modification of the amino acid arginine is…
  • Abstract Number: 2168 • ACR Convergence 2024

    Two Year Data on Quality of Life, Pain and Mobility Scores After Rituximab Treatment in the Preclinical Phase of Rheumatoid Arthritis

    Giulia Frazzei1, Sophie Cramer1, Robert Landewé2, Karen Maijer3, Danielle Gerlag4, Paul Tak, MD PhD5, Niek De Vries6, Lisa van Baarsen6, Ronald Van Vollenhoven7 and Sander Tas8, 1Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, 2Amsterdam University Medical Center, Meerssen, Netherlands, 3Tergooi Hospital, Hilversum, Amsterdam, Netherlands, 4UCB, Cambridge, United Kingdom, 5Candel Therapeutics, Cambridge, United Kingdom, 6Amsterdam UMC, Amsterdam, Netherlands, 7Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 8Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

    Background/Purpose: Over the past 10 years, several trials have investigated prevention of rheumatoid arthritis (RA) by disease modifying antirheumatic drug (DMARD) therapies. Early treatment of…
  • Abstract Number: 1728 • ACR Convergence 2023

    A Novel Animal Model for Investigating the Effect of HLA-DRB1 on Atherosclerosis

    Garth Blackler, James Akingbasote, Patti Kiser, Christopher Howlett, Ewa Cairns and Lillian Barra, Western University, London, ON, Canada

    Background/Purpose: HLA-DRB1 alleles are associated with various autoimmune and inflammatory conditions, including rheumatoid arthritis, polymyalgia rheumatica, giant cell arteritis, systemic lupus erythematosus, diabetes and atherosclerotic…
  • Abstract Number: 1737 • ACR Convergence 2023

    ACPA, Anti-CarP and AAPA Can Be Detected in Saliva, but Not in Feces of Seropositive Rheumatoid Arthritis Patients – Support for Mucosal Involvement in Specific Locations in RA

    Veerle Derksen1, Klara Martinsson2, René Toes1, Daniel Sjöberg3, Thomas Huizinga1, Alf Kastbom4, Anna Svärd3 and Diane van der Woude1, 1Leiden University Medical Center, Leiden, Netherlands, 2Linköping University, Linköping, Sweden, 3Centre for Clinical Research Dalarna, Uppsala, Sweden, 4Linköping University, Stockholm, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) patients harbor antibodies against several post-translational modifications (AMPA), for example anti-citrullinated protein antibodies (ACPA), anti-carbamylated antibodies (anti-CarP) and anti-acetylated protein antibodies…
  • Abstract Number: 1742 • ACR Convergence 2023

    Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA

    Rachna Talluri1, Sudeshna Sen2, Timothy Wilson3, Adam Savage4, Mark Gillespie4, Tom Bumol4, Marie Feser1, Jill Norri5, Michael Holer1, kevin Deane1, Paul Thompson2 and Kristen Demoruelle1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2University of Massachusetts Chan Medical School, Worcester, MA, 3Thomas Jefferson University, Philadelphia, PA, 4Allen Institute for Immunology, Seattle, WA, 5Colorado School of Public Health, Denver, CO

    Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
  • Abstract Number: 1748 • ACR Convergence 2023

    Macrophage Extracellular Traps Require Peptidylarginine Deiminase 2 and 4 and Are a Source of Citrullinated Antigens Bound by Rheumatoid Arthritis Autoantibodies

    S Janna Bashar, Caitlyn Holmes and Miriam Shelef, University of Wisconsin, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis, but the sources of citrullinated antigens as well as which peptidylarginine deiminases (PADs) are…
  • Abstract Number: 1751 • ACR Convergence 2023

    Profiling of Anti-PAD IgG and IgA in Patients from the Head-to-head Adalimumab vs Abatacept Rheumatoid Arthritis AMPLE Trial and Matched Healthy Controls

    Namit Kumar1, Xueer Chen2, Mary Ann Aure3, Andy Ishii4, Laura Martinez-Prat5, chelsea Bentow4, Jasmine Saini2, Michael Mahler4 and Laurence Menard2, 1Bristol Myers Squibb, San Diego, CA, 2Bristol Myers Squibb, Princeton, NJ, 3Werfen, Chula Vista, CA, 4Werfen, San Diego, CA, 5Werfen Autoimmunity, Sant Cugat del Vallès, Spain

    Background/Purpose: A hallmark of rheumatoid arthritis (RA) is the presence of anti-citrullinated protein antibodies (ACPA) targeting neoantigens which are generated by a family of enzymes…
  • Abstract Number: 1758 • ACR Convergence 2023

    Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis

    Lucía Lourido1, Vijay Joshua2, Monika Hansson3, Ronald Sjöberg4, Elisa Pin4, Cristina Ruiz-Romero5, Peter Nilsson4, Lars Klareskog2 and Francisco J. Blanco6, 1Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, 2Karolinska Institutet, Stockholm, Sweden, 3Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, 4Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, 51) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, 6Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain

    Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…
  • Abstract Number: 2124 • ACR Convergence 2023

    Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals

    Adam Savage1, Ziyuan He1, Marla Glass1, Julian Reading1, LauraKay Moss2, Marie Feser2, Vlad Tsaltskan3, Katherine Nguyen Nguyen3, Kristen Demoruelle2, kristine Kuhn4, David Boyle3, Cate Speake5, Xiao-Jun Li1, Peter Skene1, Troy Torgerson1, Tom Bumol1, V. Michael Holers6, Jane Buckner7, Gary Firestein8, kevin Deane2 and Mark Gillespie1, 1Allen Institute for Immunology, Seattle, WA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of California San Diego, La Jolla, CA, 4University of Colorado School of Medicine, Aurora, CO, 5Benaroya Research Institute, Seattle, WA, 6University of Colorado, Denver, CO, 7Benaroya Research Institute at Virginia Mason, Seattle, WA, 8University of California San Diego, San Diego, CA

    Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
  • Abstract Number: 2144 • ACR Convergence 2023

    Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study

    Rohit Panchakshari1, Matthew Loza2, Thomas Huizinga3, Georg Schett4, Keying Ma2, Jocelyn H. Leu2, Sophia G. Liva2, Fowzia Ibrahim5, Bei Zhou6, Qingmin Wang2, Ricardo Rojo Cella2, Chetan S. Karyekar2, Kaiyin Fei2, Carolyn Cuff7 and Sheng Gao2, 1Janssen Research & Development, LLC, La Jolla, CA, 2Janssen Research & Development, LLC, Spring House, PA, 3Leiden University Medical Center, Leiden, Netherlands, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 5Janssen Research & Development, LLC, High Wycombe, United Kingdom, 6Janssen Research & Development, LLC, Chesterbrook, PA, 7Janssen Research & Development, LLC, Cambridge, MA

    Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…
  • Abstract Number: 2193 • ACR Convergence 2023

    Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement

    Augusto Silva1, Filipa Costa2, Mariana Silva2, Giovanni Fulvio3, Matilde Bandeira2, Manuel Silvério-António4, Nikita Khmelinskii2, Chiara Baldini3 and Vasco Romão2, 1Santa Maria Hospital, Maceira, Portugal, 2Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, 3University of Pisa, Pisa, Italy, 4Hospital Santa Maria, Lisboa, Portugal

    Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…
  • Abstract Number: 2433 • ACR Convergence 2023

    Longitudinal Multi-Omics Single Cell Analysis Reveals Abatacept Treatment Shifts Peripheral Lymphocyte Subpopulations in Seropositive RA with Reduction of Mature B Cells and Retention of Transitional and Naive B Cells

    Gregg Silverman1, William Rigby2, Helena Jun1, Jasmine Shwetar1, Katie Tumang1, Sergei Koralov3, Ellie Ivanova1, David Mieles1, Sladjana Skopelia-Gardner4 and Kelly Ruggles1, 1NYU Grossman School of Medicine, New York, NY, 2Hitchcock-Dartmouth Medicine Center, Hanover, NH, 3NYU Grossman Schoolof Medicine, New York, NY, 4Hitchcock-Dartmouth Medicine Center, Lebanon, NH

    Background/Purpose: Biologic agents of diverse molecular mechanisms of action are approved for RA, but we do not have a full understanding of the implications of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology